Intimate hyperpigmentation describes increased visible pigmentation affecting external intimate and adjacent intertriginous skin. It should not be approached as ordinary facial or body pigmentation simply occurring in another location.
Anatomical location changes the therapeutic context. Occlusion, friction, moisture, local sensitivity and the tendency toward inflammatory pigmentary change must all be considered before treatment intensity is selected.
Repeated mechanical contact and occlusive conditions may influence both pigmentation and treatment tolerance.
Tolerance is not uniform across intimate and adjacent cutaneous areas, making regional assessment essential.
Irritation itself can perpetuate or intensify pigmentation, particularly in patients predisposed to pigmentary change.
External cutaneous surfaces, folds and mucosal structures are not therapeutically interchangeable and must be distinguished clinically.
The first question is therefore not “How can this area be lightened?” but “What tissue are we treating, and why is it pigmented?”
“Intimate hyperpigmentation” may involve several external cutaneous regions. Each exists within a different anatomical environment and should therefore be identified precisely before treatment is considered.
The anatomical treatment field must be defined before the therapeutic pathway.External cutaneous surfaces and mucosal structures are anatomically distinct and must not be considered therapeutically interchangeable.
Pigmentation may involve external keratinized skin, particularly the labia majora and immediately adjacent cutaneous surfaces.
Groin pigmentation develops within an intertriginous environment where repeated contact, occlusion and moisture may influence the clinical presentation.
Pigmentation may extend beyond the folds onto adjacent thigh skin, where mechanical contact and previous inflammatory episodes may contribute to visible change.
External perianal pigmentation represents a distinct anatomical context in which the cutaneous treatment field must be defined with particular precision.
Location defines the treatment field — not the protocol. Once the anatomical area has been identified, the next step is to determine the mechanism responsible for the pigmentation.
Product selection follows the therapeutic objective. Corrective acids, post-acid transition products and metabolic regulators do not occupy the same position within the treatment sequence.
Select the pathway first, then place each product in its correct clinical sequence.The order of application is fundamental. Peeling de Luxe Plus occupies the transition between the corrective acid step and subsequent metabolic products.
Controlled acid application according to the selected corrective objective.
Applied after the acid step and before subsequent metabolic products.
Sequence rule: Peeling de Luxe Plus is positioned after an acid such as TCA or salicylic acid and before the application of other metabolic products.
Used when the selected therapeutic pathway includes a direct corrective step against established visible pigmentation.
A controlled corrective option when a frosting-based pathway has been selected and the anatomical treatment field is considered suitable.
An alternative corrective acid approach when clinically appropriate within the selected treatment strategy.
A specific intermediate step within the corrective sequence, positioned after the acid application and before subsequent metabolic products.
Peeling de Luxe Plus is not positioned as an isolated first-line acid step in this sequence. Its role follows the corrective acid application and precedes the products selected for subsequent metabolic management.
Post-Acid Position Used after the selected corrective acid step.
Frosting-Control Role Marks the controlled transition following the corrective acid phase.
Pre-Metabolic Position Applied before subsequent metabolic products.
Do not reverse the sequence: metabolic products belong after Peeling de Luxe Plus when the protocol includes a preceding corrective acid.
Metabolic products are selected according to the pigmentary objective and their intended role within the regulatory strategy.
Positioned within the metabolic strategy for regulation of melanocyte activity and melanin-related pigmentation processes.
A depigmenting component of the metabolic strategy, combining progressive pigment management with biological photoprotection against UVA- and UVB-related environmental stimulation.
Used within a metabolic strategy where enhanced penetration of associated active components forms part of the intended treatment logic.
The same product sequence is not required for every patient. Selection depends on whether the objective is direct correction, progressive metabolic regulation or a planned combination of both.
Selected when controlled correction of established visible pigmentation is the principal initial objective.
Selected when the therapeutic objective is progressive regulation rather than an initial frosting-based corrective step.
Used when controlled correction is deliberately integrated with subsequent metabolic management.
When the selected protocol begins with TCA, salicylic acid or another appropriate corrective acid, Peeling de Luxe Plus follows that acid step. Other metabolic products are applied only after this transition step within the intended protocol.
Product selection defines the therapeutic tools. The next step is to organize them longitudinally through correction, stabilization and maintenance.
